ClinicalTrials.gg
CompletedNCT00540293AT GOALUpdated Mar 12, 2021Results posted

Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study

A Phase 4 interventional study of Atorvastatin in Dyslipidemias, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 20 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-12.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
425
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 47 studies testing atorvastatin in Dyslipidemias — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Dyslipidemias.

Enrollment
11th of 47
425 · median 165
Started
2007
with 3 others
Phase 4
22 of 47
1 open now
Registered
11th of 47
by date
Lead sponsor
9 of 47
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 47 studies testing atorvastatin in Dyslipidemias, this one is the 11th largest by enrollment, is one of 4 that started in 2007, is one of 22 in phase 4, and was the 11th registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

1 of the 47 studies testing atorvastatin in Dyslipidemias is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing atorvastatin in Dyslipidemias, or all of them as a file.
02

Study summary

To evaluate the percentage of Korean dyslipidemic subjects in the total group and each cardiovascular risk group achieving LDL-C target as defined by NCEP ATP Ⅲ criteria at starting doses of 10mg, 20mg and 40mg of atorvastatin after 8 weeks of treatment.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a Korean , dyslipidemic outpatient
  2. Is eligible for LDL-lowering drug therapy at screening and baseline as determined by the following LDL-cholesterol (LDL-C) cut-off points defined by NCEP ATP Ⅲ: 2. 1 LDL-C ≥ 190 mg/dL for subjects with 0 or 1 CHD risk factor 2. 2 LDL-C ≥ 160 mg/dL for subjects with 2 or more CHD risk factors and 10 year risk \< 10 % 2. 3 LDL-C ≥ 130 mg/dL for subjects with 2 or more CHD risk factors and 10 year risk 10-20 % 2. 4 LDL-C ≥ 100 mg/dL for subjects with documented CHD or CHD risk equivalents (10-year risk > 20 %)
  3. Has LDL-C ≤ 220mg/dL at baseline 4. Has triglyceride level ≤ 600mg/dL at baseline

Exclusion criteria

Exclusion Criteria:

  1. Is pregnant or lactating
  2. Has present myopathy or history of myopathy or has personal or familial history of hereditary muscular disorders or any history of rhabdomyolysis
  3. Has history of intolerance or to atorvastatin or other statins
  4. Uncontrolled hypertension (i.e. moderate hypertension, sitting systolic BP ≥ 160mmHg and/or diastolic BP ≥ 100mmHg)
  5. Has HbAlc > 10%
  6. Has any severe disease of has had any major problem or surgical procedure within the 3 months prior to screening that is likely to jeopardize the planned termination of the study. (e.g., any carcinoma, coronary angioplasty, coronary artery bypass graft, cardiac infarct, severe or unstable angina pectoris)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
425 participants (actual)

Study arms

  • Experimental
    Treatment group

    this patient group consists of dyslipidemia patients with various CVD risk factors

    Drug: Atorvastatin

Interventions

  • Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group

06

What researchers measure

Primary outcomes

  1. Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.

    LDL-C Responders by visit and by risk group - full analysis set (FAS)

    Time frame: Week 8

Secondary outcomes

  1. Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.

    LDL-C Responders by visit and by risk group - FAS

    Time frame: Week 4

  2. Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment

    Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride

    Time frame: Weeks 4 and 8

  3. Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment

    Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride

    Time frame: weeks 4 and 8

  4. Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.

    LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)

    Time frame: 8 weeks

  5. Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.

    LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)

    Time frame: 8 weeks

  6. Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment

    Median baseline, and change from baseline in hs-CRP by risk group - FAS

    Time frame: 4 and 8 weeks

  7. Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment

    Percent change from baseline in hs-CRP by risk group - FAS

    Time frame: 4 and 8 weeks

  8. Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.

    Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS

    Time frame: Baseline, and 8 weeks

  9. Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.

    Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS

    Time frame: 8 weeks

07

Results

Posted Jun 26, 2009

Participant flow

Study was conducted at 20 centers in Korea

Participant flow — Overall Study
MilestoneTotal Treatment Group (All Subjects Who Received Atorvastatin)
Started425
Completed390
Not completed35
Withdrew: Adverse event related to study drug10
Withdrew: Adverse event not related to study drug7
Withdrew: Withdrawal by subject6
Withdrew: Protocol violation, & subject schedule12

Outcome measures

SecondaryPercent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.

LDL-C Responders by visit and by risk group - FAS

Time frame:
Week 4
Reported as:
Mean · Percent subjects achieved LDL-C target
Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.
Percent subjects achieved LDL-C targetTotalLow RiskMedium RiskHigh Risk
Percent of Subjects in the Total Group and Each Cardiovascular Risk Group Achieving LDL-C Target After 4 Weeks of Treatment.81.9 (77.9 to 85.5)85.7 (67.3 to 96.0)95.5 (84.5 to 99.4)79.9 (75.2 to 84.0)
SecondaryChanges in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment

Mean baseline, change and percent change from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride

Time frame:
Weeks 4 and 8
Reported as:
Mean · mg/dL (ratio for Scalar)
Changes in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment
mg/dL (ratio for Scalar)TotalLow RiskMedium RiskHigh Risk
LDL-C baseline151.7 (149.1 to 154.4)187.0 (179.8 to 194.1)160.6 (154.3 to 167.0)147.7 (144.9 to 150.5)
LDL-C (week 4)-63.5 (-66.2 to -60.8)-73.8 (-82.7 to -64.8)-65.1 (-73.5 to -56.7)-62.4 (-65.4 to -59.4)
LDL-C (week 8)-65.3 (-68.0 to -62.5)-77.6 (-88.3 to -66.9)-64.2 (-72.4 to -56.0)-64.4 (-67.4 to -61.4)
HDL-C baseline48.3 (47.3 to 49.3)50.5 (47.4 to 53.7)48.0 (45.5 to 50.5)48.2 (47.0 to 49.3)
HDL-C (week 4)0.1 (-0.7 to 0.9)-0.8 (-3.6 to 2.0)3.3 (0.9 to 5.7)-0.2 (-1.1 to 0.7)
HDL-C (week 8)0.5 (-0.4 to 1.3)2.1 (-1.6 to 5.9)3.0 (0.9 to 5.1)0.0 (-1.0 to 1.0)
Non-HDL-C baseline175.5 (172.5 to 178.5)209.9 (201.0 to 218.8)187.1 (179.9 to 194.4)171.1 (167.9 to 174.4)
Non-HDL-C (week 4)-69.4 (-72.3 to -66.5)-75.4 (-87.8 to -63.1)-71.3 (-80.2 to -62.5)-68.6 (-71.8 to -65.4)
Non-HDL-C (week 8)-70.7 (-73.7 to -67.7)-80.9 (-93.9 to -67.8)-72.1 (-80.3 to -64.0)-69.7 (-73.0 to -66.4)
LDL-C/HDL-C ratio baseline3.2 (3.1 to 3.3)3.7 (3.4 to 4.0)3.4 (3.2 to 3.6)3.2 (3.1 to 3.3)
LDL-C/HDL-C Ratio (Scalar) week 4-1.4 (-1.4 to -1.3)-1.4 (-1.7 to -1.1)-1.5 (-1.7 to -1.3)-1.3 (-1.4 to -1.3)
LDL-C/HDL-C Ratio (Scalar) week 8-1.4 (-1.5 to -1.3)-1.6 (-1.9 to -1.2)-1.5 (-1.7 to -1.3)-1.4 (-1.5 to -1.3)
TC baseline223.9 (220.8 to 227.0)262.3 (253.9 to 270.8)235.1 (228.0 to 242.3)219.3 (216.0 to 222.6)
TC (week 4)-69.4 (-72.4 to -66.4)-78.2 (-89.3 to -67.1)-68.0 (-77.2 to -58.8)-68.8 (-72.2 to -65.5)
TC (week 8)-70.4 (-73.4 to -67.3)-80.7 (-94.2 to -67.3)-69.1 (-77.2 to -61.1)-69.7 (-73.1 to -66.2)
TG baseline154.1 (146.2 to 162.1)150.7 (128.6 to 172.8)152.3 (130.3 to 174.2)154.7 (145.6 to 163.7)
TG (week 4)-29.1 (-35.5 to -22.7)-11.5 (-43.0 to 20.0)-16.6 (-31.4 to -1.8)-32.1 (-39.2 to -25.1)
TG (week 8)-29.3 (-37.9 to -20.7)-20.9 (-51.3 to 9.5)-18.5 (-36.3 to -0.7)-31.4 (-41.3 to -21.5)
SecondaryPercent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment

Mean percent changes from baseline in lipid parameters by risk group - FAS. HDL-C: high density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride

Time frame:
weeks 4 and 8
Reported as:
Mean · Percent
Percent Changes From Baseline in Lipid Parameters in Subjects in the Total Group and Each Cardiovascular Risk Group After 4 and 8 Weeks of Treatment
PercentTotalLow RiskMedium RiskHigh Risk
LDL-C % change from baseline (week 4)-40.9 (-42.3 to -39.5)-39.5 (-44.1 to -35.0)-39.6 (-43.8 to -35.5)-41.2 (-42.8 to -39.6)
LDL-C % change from baseline (week 8)-42.0 (-43.4 to -40.7)-41.2 (-46.6 to -35.8)-39.3 (-43.5 to -35.1)-42.5 (-44.0 to -41.0)
HDL-C % change from baseline (week 4)1.7 (0.0 to 3.4)-0.2 (-6.0 to 5.6)7.7 (2.3 to 13.1)1.1 (-0.8 to 2.9)
HDL-C % change from baseline (week 8)2.6 (0.8 to 4.4)5.6 (-2.1 to 13.2)6.7 (2.3 to 11.1)1.8 (-0.2 to 3.9)
Non-HDL-C % change from baseline (week 4)-38.7 (-40.1 to -37.4)-35.5 (-40.9 to -30.1)-37.7 (-41.5 to -33.8)-39.1 (-40.6 to -37.7)
Non-HDL-C % change from baseline (week 8)-39.4 (-40.7 to -38.1)-38.2 (-44.1 to -32.2)-38.3 (-42.1 to -34.5)-39.7 (-41.1 to -38.2)
LDL-C/HDL-C ratio % change from baseline (week 4)-41.3 (-43.0 to -39.7)-36.7 (-44.3 to -29.0)-44.1 (-48.9 to -39.3)-41.4 (-43.2 to -39.6)
LDL-C/HDL-C ratio % change from baseline (week 8)-42.6 (-44.3 to -40.9)-41.6 (-49.5 to -33.7)-42.9 (-48.0 to -37.7)-42.6 (-44.5 to -40.8)
TC % change from baseline (week 4)-30.3 (-31.4 to -29.2)-29.7 (-33.6 to -25.7)-28.5 (-31.9 to -25.2)-30.6 (-31.9 to -29.3)
TC % change from baseline (week 8)-30.7 (-31.9 to -29.6)-30.4 (-35.2 to -25.5)-29.2 (-32.3 to -26.2)-31.0 (-32.2 to -29.7)
TG % change from baseline (week 4)-8.2 (-12.9 to -3.6)4.4 (-18.5 to 27.3)-8.3 (-17.7 to 1.2)-9.3 (-14.4 to -4.1)
TG % change from baseline (week 8)-9.8 (-14.9 to -4.8)-6.3 (-27.0 to 14.5)-7.0 (-20.4 to 6.4)-10.5 (-16.2 to -4.8)
SecondarySubjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.

LDL-C responders at week 8 by titration status and risk groups - FAS, efficacy evaluation (EVAL), and FAS (no last observation carried forward, LOCF)

Time frame:
8 weeks
Reported as:
Number · Participants
Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.
ParticipantsTotalLow RiskMedium RiskHigh Risk
FAS population responders no titration3392441274
FAS population responders 1-step titration563152
EVAL population responders no titration3052239244
EVAL population responders 1-step titration533149
FAS population (no LOCF) no titration3362441271
FAS population (no LOCF) 1-step titration563152
SecondaryPercent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.

LDL-C responders at week 8 by titration status and risk groups - FAS, efficay evaluation (EVAL), and FAS (no last observation carried forward, LOCF)

Time frame:
8 weeks
Reported as:
Mean · percentage of participants
Percent of Subjects Who Achieved LDL-C Target With no Titration of Atorvastatin and After One Step Titration of Atorvastatin.
percentage of participantsTotalLow RiskMedium RiskHigh Risk
FAS population, no titration89.1 (85.3 to 92.2)95.8 (78.9 to 99.9)97.6 (87.1 to 99.9)87.2 (82.7 to 90.9)
FAS population, 1-step titration82.1 (69.6 to 91.1)100.0 (29.2 to 100.0)100.0 (2.5 to 100.0)80.8 (67.5 to 90.4)
EVAL population, no titration91.1 (87.4 to 94.1)95.5 (77.2 to 99.9)97.4 (86.5 to 99.9)89.8 (85.2 to 93.3)
EVAL population, 1-step titration83.0 (70.2 to 91.9)100.0 (29.2 to 100.0)100.0 (2.5 to 100.0)81.6 (68.0 to 91.2)
FAS population (no LOCF), no titration89.0 (85.1 to 92.1)95.8 (78.9 to 99.9)97.6 (87.1 to 99.9)87.1 (82.5 to 90.8)
FAS population (no LOCF), 1-step titration82.1 (69.6 to 91.1)100.0 (29.2 to 100.0)100.0 (2.5 to 100.0)80.8 (67.5 to 90.4)
SecondaryChange From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment

Median baseline, and change from baseline in hs-CRP by risk group - FAS

Time frame:
4 and 8 weeks
Reported as:
Median · mg/dL
Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment
mg/dLTotalLow RiskMedium RiskHigh Risk
Baseline0.108 (0.094 to 0.126)0.082 (0.060 to 0.112)0.075 (0.059 to 0.126)0.122 (0.102 to 0.137)
Median change from baseline (week 4)-0.008 (-0.014 to -0.005)-0.008 (-0.028 to -0.001)-0.002 (-0.014 to 0.023)-0.010 (-0.018 to -0.005)
Median change from baseline (week 8)-0.015 (-0.021 to -0.009)-0.011 (-0.034 to 0.018)-0.001 (-0.021 to 0.010)-0.018 (-0.027 to -0.010)
PrimaryPercent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.

LDL-C Responders by visit and by risk group - full analysis set (FAS)

Time frame:
Week 8
Reported as:
Mean · Percentage of participants
Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.
Percentage of participantsTotalLow RiskMedium RiskHigh Risk
Percent of Subjects in the Total and Each Cardiovascular Risk Group Achieving Low Density Lipoprotein-cholesterol (LDL-C) Target After 8 Weeks of Treatment.86.0 (82.3 to 89.2)92.9 (76.5 to 99.1)95.5 (84.5 to 99.4)84.3 (80.0 to 87.9)
SecondaryPercent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment

Percent change from baseline in hs-CRP by risk group - FAS

Time frame:
4 and 8 weeks
Reported as:
Median · percentage
Percent Change From Baseline in High Sensitive Circulating C-reactive Protein (Hs-CRP) After 4 and 8 Weeks of Treatment
percentageTotalLow RiskMedium RiskHigh Risk
Median % change from baseline (week 4)-12.346 (-21.429 to -4.651)-13.941 (-35.055 to -1.923)-2.553 (-22.951 to 25.926)-16.197 (-24.182 to -4.523)
Median % change from baseline (week 8)-18.605 (-24.138 to -11.111)-18.621 (-37.363 to 20.690)-1.472 (-26.364 to 14.925)-20.561 (-25.333 to -12.346)
SecondaryChanges From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.

Median baseline, and change from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS

Time frame:
Baseline, and 8 weeks
Reported as:
Median · pg/dL
Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.
pg/dLTotalLow RiskMedium RiskHigh Risk
MCP-1 baseline302.7 (295.0 to 311.7)305.2 (267.9 to 340.6)317.7 (294.2 to 386.4)301.6 (291.7 to 310.0)
MCP-1 change from baseline (week 8)39.8 (21.3 to 66.7)-15.0 (-61.4 to 45.9)-22.4 (-102.9 to 42.6)59.4 (33.6 to 74.9)
IL-6 baseline0.40 (0.40 to 0.50)0.30 (0.10 to 0.60)0.40 (0.30 to 0.80)0.50 (0.40 to 0.60)
IL-6 change from baseline (week 8)0.00 (0.00 to 0.00)0.00 (-0.30 to 0.00)-0.10 (-0.30 to 0.00)0.00 (0.00 to 0.00)
TNF-alpha baseline0.10 (0.10 to 0.10)0.10 (0.10 to 0.30)0.20 (0.10 to 0.30)0.10 (0.10 to 0.10)
TNF-alpha change from baseline (week 8)0.00 (0.00 to 0.00)0.00 (-0.10 to 0.00)0.00 (-0.10 to 0.00)0.00 (0.00 to 0.00)
SecondaryPercent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.

Percent changes from baseline in monocyte chemoattractant protein (MCP-1), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) by risk group - FAS

Time frame:
8 weeks
Reported as:
Median · percent
Percent Changes From Baseline in Selected Inflammatory Markers After 8 Weeks of Treatment.
percentTotalLow RiskMedium RiskHigh Risk
MCP-1 % change (week 8)14.0 (7.8 to 22.3)-5.6 (-18.6 to 18.7)-8.0 (-34.2 to 21.4)18.2 (11.1 to 24.7)
IL-6 % change (week 8)0.00 (0.00 to 0.00)0.00 (-50.00 to 0.00)-12.50 (-45.45 to 25.00)0.00 (0.00 to 0.00)
TNF-alpha % change (week 8)0.00 (0.00 to 0.00)0.00 (-50.00 to 0.00)0.00 (-42.86 to 0.00)0.00 (0.00 to 0.00)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Treatment Group (All Subjects Who Received Atorvastatin)———
Most frequent serious events
Most frequent serious events
EventTotal Treatment Group (All Subjects Who Received Atorvastatin)
Cerabral infarctionNervous system disorders2/425
Wrist fractureInjury, poisoning and procedural complications1/425
Most frequent other events
Most frequent other events
EventTotal Treatment Group (All Subjects Who Received Atorvastatin)
NasopharyngitisInfections and infestations8/425
HeadacheNervous system disorders6/425

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Total Treatment Group (All Subjects Who Received Atorvastatin)
Females between 18 and 80 years62.9 ± 8.6
Males between 18 and 80 years58.6 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Total Treatment Group (All Subjects Who Received Atorvastatin)
Female195
Male230
08

Study locations

20 sites
  • Pfizer Investigational Site
    Daegu, Korea 705-717, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, Korea 135-710, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 602-739, Korea, Republic of
  • Pfizer Investigational Site
    Busan, 614-735, Korea, Republic of
  • Pfizer Investigational Site
    Daegu, 700-712, Korea, Republic of
  • Pfizer Investigational Site
    Daejeon, 302-718, Korea, Republic of
  • Pfizer Investigational Site
    Gwangju, 501-757, Korea, Republic of
  • Pfizer Investigational Site
    Gwangju, 503-715, Korea, Republic of
  • Pfizer Investigational Site
    Gyeonggi-do, 431-070, Korea, Republic of
  • Pfizer Investigational Site
    Gyeonggi-do, 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Incheon, 405-760, Korea, Republic of
  • Pfizer Investigational Site
    Kyunggi-do, 420-717, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-746, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 120-752, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 134-010, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 136-705, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 137-701, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 138-736, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 143-914, Korea, Republic of
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2007
First posted
Oct 8, 2007
Start
Oct 2007
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jun 26, 2009
Last update
Mar 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00540293
Responsible party
Sponsor
First posted
Oct 8, 2007
Start date
Oct 2007
Primary completion
May 2008
Completion
May 2008
Results posted
Jun 26, 2009
Last update
Mar 12, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion